FN3 Domain Molecules for EGFR c-Met Binding Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current small molecule and antibody-based therapeutic approaches for targeting EGFR and c-Met signaling pathways are limited by lack of specificity, potential off-target activity, and dose-limiting toxicity, as well as challenges with receptor clustering and activation.
Innovation Solution
Development of monospecific and bispecific FN3 domain-containing molecules that specifically bind to EGFR and c-Met, blocking the binding of their respective ligands and inhibiting downstream signaling pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule inhibitors are used to target EGFR and c-Met, then therapeutic intervention is achieved, but specificity is reduced and off-target activity increases
Solution Approach 1:
The patent divides the therapeutic approach into separate monospecific and bispecific FN3 domain molecules, each targeting either EGFR or c-Met individually or in combination. This segmentation allows for precise control over which receptor is inhibited, avoiding the off-target effects associated with small molecule inhibitors that may bind multiple sites non-specifically.
Solution Approach 2:
The FN3 domain acts as an intermediary binding molecule that specifically recognizes and binds to EGFR or c-Met receptors. Unlike small molecule inhibitors that may have promiscuous binding, the FN3 domain provides a structured, high-affinity interaction that enhances specificity while blocking ligand binding and downstream signaling.
2Reliability
If small molecule inhibitors are used to target EGFR and c-Met, then therapeutic intervention is achieved, but toxicity increases due to dose-limiting side effects
Solution Approach 1:
The patent segments the therapeutic function into distinct FN3 domain molecules that can be administered separately or in combination. This allows for optimized dosing of each molecule based on its specific target and toxicity profile, avoiding the cumulative toxicity of small molecule inhibitors that require high doses to achieve efficacy.
Solution Approach 2:
The patent changes the molecular parameters from small molecule inhibitors to protein-based FN3 domains, which have different pharmacokinetic and pharmacodynamic properties. This parameter change results in reduced toxicity while maintaining or improving therapeutic efficacy, as the FN3 domains can achieve potent inhibition at lower effective doses.
3Reliability
If conventional antibody therapies are used to target EGFR and c-Met, then receptor binding is achieved, but receptor clustering and activation occur causing side effects
Solution Approach 1:
The patent employs monospecific FN3 domains that bind to only one receptor type (either EGFR or c-Met) at a time, preventing the cross-linking and clustering that occurs with bivalent or bispecific antibodies. This monovalent binding approach blocks ligand interaction without inducing receptor aggregation and subsequent downstream signaling.
Solution Approach 2:
The FN3 domains are designed as stable but not permanently cross-linking binding units. Unlike conventional antibodies that may form stable immune complexes, the FN3 domains provide transient, reversible binding that blocks receptor activation without causing prolonged clustering or activation of complement systems.
4Reliability
If conventional antibody therapies are used to target EGFR and c-Met, then therapeutic coverage is achieved, but tissue penetration is limited
Solution Approach 1:
The patent divides the therapeutic coverage into smaller FN3 domain molecules that have reduced molecular weight and size compared to full-length antibodies. This segmentation enables better penetration into solid tumors and other tissues while maintaining the ability to bind and inhibit EGFR and c-Met signaling pathways effectively.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The FN3 domain-containing molecules demonstrate enhanced specificity and reduced off-target toxicity compared to small molecule inhibitors, with improved tissue penetration and potent inhibition of EGFR and c-Met signaling, leading to effective tumor growth inhibition.
Implementation Method 1
the first FN3 domain specifically binds epidermal growth factor receptor (EGFR) and blocks binding of epidermal growth factor (EGF) to EGFR, and the second FN3 domain specifically binds hepatocyte growth factor receptor (c-Met), and blocks binding of hepatocyte growth factor (HGF) to c-Met
Data Source
AI summary
Monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.